These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1093 related articles for article (PubMed ID: 18249372)

  • 21. Gonadotrophin stimulation for in vitro fertilization significantly alters the hormone milieu in follicular fluid: a comparative study between natural cycle IVF and conventional IVF.
    von Wolff M; Kollmann Z; Flück CE; Stute P; Marti U; Weiss B; Bersinger NA
    Hum Reprod; 2014 May; 29(5):1049-57. PubMed ID: 24608520
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Anti-Müllerian hormone levels to predict oocyte maturity and embryo quality during controlled ovarian hyperstimulation.
    Melado Vidales L; Fernández-Nistal A; Martínez Fernández V; Verdú Merino V; Bruna Catalán I; Bajo Arenas JM
    Minerva Ginecol; 2017 Jun; 69(3):225-232. PubMed ID: 27352270
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Anti-Müllerian hormone is highly expressed and secreted from cumulus granulosa cells of stimulated preovulatory immature and atretic oocytes.
    Kedem-Dickman A; Maman E; Yung Y; Yerushalmi GM; Hemi R; Hanochi M; Dor J; Hourvitz A
    Reprod Biomed Online; 2012 May; 24(5):540-6. PubMed ID: 22421733
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Anti-Mullerian hormone dynamics during controlled ovarian hyperstimulation and optimal timing of measurement for outcome prediction.
    Lee JR; Kim SH; Kim SM; Jee BC; Ku SY; Suh CS; Choi YM; Kim JG; Moon SY
    Hum Reprod; 2010 Oct; 25(10):2597-604. PubMed ID: 20729237
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Serum and follicular endocrine profile is different in modified natural cycles than in cycles stimulated with gonadotropin and gonadotropin-releasing hormone antagonist.
    Jancar N; Virant-Klun I; Bokal EV
    Fertil Steril; 2009 Dec; 92(6):2069-71. PubMed ID: 19815198
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Levels of the epidermal growth factor-like peptide amphiregulin in follicular fluid reflect the mode of triggering ovulation: a comparison between gonadotrophin-releasing hormone agonist and urinary human chorionic gonadotrophin.
    Humaidan P; Westergaard LG; Mikkelsen AL; Fukuda M; Yding Andersen C
    Fertil Steril; 2011 May; 95(6):2034-8. PubMed ID: 21377153
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Effect of ovarian stimulation with recombinant follicle-stimulating hormone, gonadotropin-releasing hormone agonist and antagonists, on follicular fluid stem cell factor and serum urocortin 1 levels on the day of oocyte retrieval.
    Celik O; Celik E; Yilmaz E; Celik N; Turkcuoglu I; Ulas M; Kumbak B; Aktan E; Ozerol I
    Arch Gynecol Obstet; 2013 Dec; 288(6):1417-22. PubMed ID: 23801011
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Supplementation with a recombinant human chorionic gonadotropin microdose leads to similar outcomes in ovarian stimulation with recombinant follicle-stimulating hormone using either a gonadotropin-releasing hormone agonist or antagonist for pituitary suppression.
    Cavagna M; Maldonado LG; de Souza Bonetti TC; de Almeida Ferreira Braga DP; Iaconelli A; Borges E
    Fertil Steril; 2010 Jun; 94(1):167-72. PubMed ID: 19342035
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Serum antimüllerian hormone/müllerian-inhibiting substance appears to be a more discriminatory marker of assisted reproductive technology outcome than follicle-stimulating hormone, inhibin B, or estradiol.
    Hazout A; Bouchard P; Seifer DB; Aussage P; Junca AM; Cohen-Bacrie P
    Fertil Steril; 2004 Nov; 82(5):1323-9. PubMed ID: 15533354
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Multifollicular recruitment in combination with gonadotropin-releasing hormone antagonist increased pregnancy rates in intrauterine insemination cycles.
    Gómez-Palomares JL; Acevedo-Martín B; Chávez M; Manzanares M; Ricciarelli E; Hernández ER
    Fertil Steril; 2008 Mar; 89(3):620-4. PubMed ID: 17678911
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Comparison of GnRH agonists and antagonists in an ovular donation program].
    Saucedo de la Llata E; Moraga Sánchez MR; Batiza Reséndiz V; Santos Haliscak R; Galache Vega P; Hernández Ayup S
    Ginecol Obstet Mex; 2004 Feb; 72():53-6. PubMed ID: 15216901
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Correlations between anti-müllerian hormone, inhibin B, and activin A in follicular fluid in IVF/ICSI patients for assessing the maturation and developmental potential of oocytes.
    Cupisti S; Dittrich R; Mueller A; Strick R; Stiegler E; Binder H; Beckmann MW; Strissel P
    Eur J Med Res; 2007 Dec; 12(12):604-8. PubMed ID: 18024272
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Subtle progesterone rise in the single-dose gonadotropin-releasing hormone antagonist (cetrorelix) stimulation protocol in patients undergoing in vitro fertilization or intracytoplasmic sperm injection cycles.
    Seow KM; Lin YH; Huang LW; Hsieh BC; Huang SC; Chen CY; Chen PH; Tzeng CR; Hwang JL
    Gynecol Endocrinol; 2007 Jun; 23(6):338-42. PubMed ID: 17616858
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Comparisons of different dosages of gonadotropin-releasing hormone (GnRH) antagonist, short-acting form and single, half-dose, long-acting form of GnRH agonist during controlled ovarian hyperstimulation and in vitro fertilization.
    Hsieh YY; Chang CC; Tsai HD
    Taiwan J Obstet Gynecol; 2008 Mar; 47(1):66-74. PubMed ID: 18400585
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Follicular fluid levels of anti-Mullerian hormone as a predictor of oocyte maturation, fertilization rate, and embryonic development in patients with polycystic ovary syndrome.
    Mashiach R; Amit A; Hasson J; Amzalzg S; Almog B; Ben-Yosef D; Lessing JB; Limor R; Azem F
    Fertil Steril; 2010 May; 93(7):2299-302. PubMed ID: 19261276
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Ovarian response and follicular development for single-dose and multiple-dose protocols for gonadotropin-releasing hormone antagonist administration.
    Lee TH; Wu MY; Chen HF; Chen MJ; Ho HN; Yang YS
    Fertil Steril; 2005 Jun; 83(6):1700-7. PubMed ID: 15950639
    [TBL] [Abstract][Full Text] [Related]  

  • 37. HCG (1500IU) administration on day 3 after oocytes retrieval, following GnRH-agonist trigger for final follicular maturation, results in high sufficient mid luteal progesterone levels - a proof of concept.
    Haas J; Kedem A; Machtinger R; Dar S; Hourvitz A; Yerushalmi G; Orvieto R
    J Ovarian Res; 2014 Apr; 7():35. PubMed ID: 24694069
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Ovarian response and pregnancy outcome in poor-responder women: a randomized controlled trial on the effect of luteinizing hormone supplementation on in vitro fertilization cycles.
    Barrenetxea G; Agirregoikoa JA; Jiménez MR; de Larruzea AL; Ganzabal T; Carbonero K
    Fertil Steril; 2008 Mar; 89(3):546-53. PubMed ID: 17531989
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Flexibility in starting ovarian stimulation at different phases of the menstrual cycle for treatment of infertile women with the use of in vitro fertilization or intracytoplasmic sperm injection.
    Qin N; Chen Q; Hong Q; Cai R; Gao H; Wang Y; Sun L; Zhang S; Guo H; Fu Y; Ai A; Tian H; Lyu Q; Daya S; Kuang Y
    Fertil Steril; 2016 Aug; 106(2):334-341.e1. PubMed ID: 27114329
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Can pregnancy rate be improved in gonadotropin-releasing hormone (GnRH) antagonist cycles by administering GnRH agonist before oocyte retrieval? A prospective, randomized study.
    Schachter M; Friedler S; Ron-El R; Zimmerman AL; Strassburger D; Bern O; Raziel A
    Fertil Steril; 2008 Oct; 90(4):1087-93. PubMed ID: 18023439
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 55.